Nevro Corp (NVRO)

$17.19

-0.13

(-0.75%)

Market is closed - opens 8 PM, 21 Feb 2024

Insights on Nevro Corp

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 108.80M → 103.86M (in $), with an average decrease of 4.6% per quarter

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 108.80M → 103.86M (in $), with an average decrease of 4.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -35.02M → -23.47M (in $), with an average increase of 23.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -35.02M → -23.47M (in $), with an average increase of 23.5% per quarter

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 32.7% return, outperforming this stock by 84.6%

  • Vs SYK

    In the last 1 year, Stryker Corporation has given 32.7% return, outperforming this stock by 84.6%

  • Vs SYK

    In the last 3 years, Stryker Corporation has given 44.3% return, outperforming this stock by 134.4%

  • Vs SYK

    In the last 3 years, Stryker Corporation has given 44.3% return, outperforming this stock by 134.4%

Performance

  • $16.96
    $17.52
    $17.19
    downward going graph

    1.34%

    Downside

    Day's Volatility :3.2%

    Upside

    1.88%

    downward going graph
  • $13.98
    $39.67
    $17.19
    downward going graph

    18.67%

    Downside

    52 Weeks Volatility :64.76%

    Upside

    56.67%

    downward going graph

Returns

PeriodNevro CorpSector (Health Care)Index (Russel 2000)
3 Months
4.46%
12.9%
0.0%
6 Months
-4.94%
9.1%
0.0%
1 Year
-48.77%
10.3%
-9.1%
3 Years
-89.71%
27.3%
-22.0%

Highlights

Market Capitalization
619.6M
Book Value
$7.89
Earnings Per Share (EPS)
-2.87
PEG Ratio
-3.13
Wall Street Target Price
21.47
Profit Margin
-24.22%
Operating Margin TTM
-24.61%
Return On Assets TTM
-11.45%
Return On Equity TTM
-33.55%
Revenue TTM
422.8M
Revenue Per Share TTM
11.82
Quarterly Revenue Growth YOY
3.4000000000000004%
Gross Profit TTM
276.4M
EBITDA
-100.4M
Diluted Eps TTM
-2.87
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.8
EPS Estimate Next Year
-2.49
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.48

Analyst Recommendation

Hold
    17%Buy
    52%Hold
    30%Sell
Based on 23 Wall street analysts offering stock ratings for Nevro Corp(by analysts ranked 0 to 5 stars)
Based on 23 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
4
4
4
Hold
12
12
12
Sell
7
7
7

Analyst Forecast

What analysts predicted

Upside of 24.9%

Current $17.19
Target $21.47

Company Financials

FY18Y/Y Change
Revenue
387.3M
↑ 18.56%
Net Income
-49.2M
↑ 34.23%
Net Profit Margin
-12.7%
↓ 1.48%
FY19Y/Y Change
Revenue
390.3M
↑ 0.77%
Net Income
-103.7M
↑ 110.72%
Net Profit Margin
-26.57%
↓ 13.87%
FY20Y/Y Change
Revenue
362.0M
↓ 7.23%
Net Income
-83.1M
↓ 19.89%
Net Profit Margin
-22.94%
↑ 3.63%
FY21Y/Y Change
Revenue
386.9M
↑ 6.87%
Net Income
-131.4M
↑ 58.14%
Net Profit Margin
-33.95%
↓ 11.01%
FY22Y/Y Change
Revenue
406.4M
↑ 5.03%
Net Income
3.0M
↓ 102.28%
Net Profit Margin
0.74%
↑ 34.69%
FY23Y/Y Change
Revenue
422.8M
↑ 4.05%
Net Income
-102.4M
↓ 3513.0%
Net Profit Margin
-24.22%
↓ 24.96%
Q2 FY22Q/Q Change
Revenue
104.2M
↑ 18.64%
Net Income
-25.0M
↓ 27.2%
Net Profit Margin
-23.98%
↑ 15.1%
Q3 FY22Q/Q Change
Revenue
100.5M
↓ 3.6%
Net Income
81.5M
↓ 426.16%
Net Profit Margin
81.13%
↑ 105.11%
Q4 FY22Q/Q Change
Revenue
113.8M
↑ 13.32%
Net Income
-19.2M
↓ 123.55%
Net Profit Margin
-16.86%
↓ 97.99%
Q1 FY23Q/Q Change
Revenue
96.3M
↓ 15.39%
Net Income
-35.0M
↑ 82.52%
Net Profit Margin
-36.36%
↓ 19.5%
Q2 FY23Q/Q Change
Revenue
108.8M
↑ 12.96%
Net Income
-24.7M
↓ 29.42%
Net Profit Margin
-22.72%
↑ 13.64%
Q3 FY23Q/Q Change
Revenue
103.9M
↓ 4.55%
Net Income
-23.5M
↓ 5.04%
Net Profit Margin
-22.61%
↑ 0.11%
FY17Y/Y Change
Total Assets
454.1M
↑ 5.45%
Total Liabilities
204.9M
↑ 12.85%
FY18Y/Y Change
Total Assets
463.1M
↑ 2.0%
Total Liabilities
217.6M
↑ 6.22%
FY19Y/Y Change
Total Assets
469.6M
↑ 1.41%
Total Liabilities
253.3M
↑ 16.39%
FY20Y/Y Change
Total Assets
789.4M
↑ 68.09%
Total Liabilities
401.0M
↑ 58.3%
FY21Y/Y Change
Total Assets
574.5M
↓ 27.22%
Total Liabilities
270.9M
↓ 32.43%
FY22Y/Y Change
Total Assets
602.4M
↑ 4.85%
Total Liabilities
278.5M
↑ 2.81%
Q2 FY22Q/Q Change
Total Assets
523.9M
↓ 1.68%
Total Liabilities
293.9M
↑ 0.49%
Q3 FY22Q/Q Change
Total Assets
605.5M
↑ 15.57%
Total Liabilities
280.6M
↓ 4.54%
Q4 FY22Q/Q Change
Total Assets
602.4M
↓ 0.51%
Total Liabilities
278.5M
↓ 0.73%
Q1 FY23Q/Q Change
Total Assets
574.4M
↓ 4.65%
Total Liabilities
273.2M
↓ 1.92%
Q2 FY23Q/Q Change
Total Assets
569.5M
↓ 0.85%
Total Liabilities
274.8M
↑ 0.58%
Q3 FY23Q/Q Change
Total Assets
561.6M
↓ 1.39%
Total Liabilities
275.9M
↑ 0.42%
FY18Y/Y Change
Operating Cash Flow
-5.7M
↓ 60.01%
Investing Cash Flow
6.4M
↑ 58.1%
Financing Cash Flow
7.8M
↓ 30.76%
FY19Y/Y Change
Operating Cash Flow
-50.2M
↑ 779.91%
Investing Cash Flow
32.3M
↑ 402.56%
Financing Cash Flow
32.1M
↑ 313.89%
FY20Y/Y Change
Operating Cash Flow
1.2M
↓ 102.37%
Investing Cash Flow
-369.9M
↓ 1244.04%
Financing Cash Flow
346.9M
↑ 980.94%
FY21Y/Y Change
Operating Cash Flow
-41.9M
↓ 3616.46%
Investing Cash Flow
201.7M
↓ 154.54%
Financing Cash Flow
-169.4M
↓ 148.83%
FY22Y/Y Change
Operating Cash Flow
24.7M
↓ 158.92%
Investing Cash Flow
64.3M
↓ 68.13%
Financing Cash Flow
-2.5M
↓ 98.55%
Q2 FY22Q/Q Change
Operating Cash Flow
-12.8M
↓ 54.84%
Investing Cash Flow
70.3M
↑ 40.35%
Financing Cash Flow
2.9M
↓ 142.72%
Q3 FY22Q/Q Change
Operating Cash Flow
79.4M
↓ 718.28%
Investing Cash Flow
-56.5M
↓ 180.41%
Financing Cash Flow
37.0K
↓ 98.72%
Q4 FY22Q/Q Change
Operating Cash Flow
-13.4M
↓ 116.92%
Investing Cash Flow
458.0K
↓ 100.81%
Financing Cash Flow
1.4M
↑ 3613.51%
Q1 FY23Q/Q Change
Operating Cash Flow
-29.3M
↑ 118.39%
Investing Cash Flow
-24.6M
↓ 5481.66%
Financing Cash Flow
-2.3M
↓ 265.43%
Q2 FY23Q/Q Change
Operating Cash Flow
-14.5M
↓ 50.53%
Investing Cash Flow
11.3M
↓ 145.74%
Financing Cash Flow
4.1M
↓ 281.35%
Q3 FY23Q/Q Change
Operating Cash Flow
-6.1M
↓ 58.01%
Investing Cash Flow
7.3M
↓ 35.4%
Financing Cash Flow
-1.0M
↓ 124.58%

Technicals Summary

Sell

Neutral

Buy

Nevro Corp is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Nevro Corp
Nevro Corp
-8.89%
-4.94%
-48.77%
-89.71%
-64.24%
Stryker Corporation
Stryker Corporation
11.5%
26.45%
33.72%
43.66%
86.15%
Abbott Laboratories
Abbott Laboratories
-0.16%
9.76%
10.0%
-6.97%
50.93%
Medtronic Plc
Medtronic Plc
-2.37%
3.44%
-1.25%
-27.07%
-9.03%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Nevro Corp
Nevro Corp
157.5
NA
-3.13
-2.8
-0.34
-0.11
NA
7.89
Stryker Corporation
Stryker Corporation
42.18
42.18
3.23
11.85
0.18
0.07
0.01
48.92
Abbott Laboratories
Abbott Laboratories
34.86
34.86
27.45
4.59
0.15
0.06
0.02
21.59
Medtronic Plc
Medtronic Plc
27.17
27.17
1.57
5.16
0.08
0.04
0.03
38.69
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Nevro Corp
Nevro Corp
Hold
$619.6M
-64.24%
157.5
-24.22%
Stryker Corporation
Stryker Corporation
Buy
$132.6B
86.15%
42.18
15.44%
Abbott Laboratories
Abbott Laboratories
Buy
$197.3B
50.93%
34.86
14.27%
Medtronic Plc
Medtronic Plc
Buy
$111.3B
-9.03%
27.17
12.84%

Institutional Holdings

  • Vanguard Group Inc

    11.69%
  • Armistice Capital, LLC

    9.55%
  • BlackRock Inc

    8.64%
  • ArrowMark Colorado Holdings, LLC (ArrowMark Partners)

    6.82%
  • BRAIDWELL LP

    4.91%
  • Rock Springs Capital Management LP

    3.35%

Company Information

headquartered in redwood city, california, nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. nevro has developed and commercialized the senza spinal cord stimulation (scs) system, an evidence-based neuromodulation platform for the treatment of chronic pain. the senza system is the only scs system that delivers nevro's proprietary hf10 therapy. the nevro® senza® scs system received ce mark in 2010, tga approval in 2011, fda approval in 2015, and is commercially available in europe, australia, and the united states.

Organization
Nevro Corp
Employees
1087
CEO
Mr. Roderick H. MacLeod
Industry
Health Technology

FAQs